What question did this study set out to answer?

This study evaluated the prevalence of claudin 18.2 expression and its prognostic value in pancreatic ductal adenocarcinoma.

May 29, 2026Journal of Clinical Oncology

Prevalence and prognostic value of Claudin 18.2 expression in pancreatic ductal adenocarcinoma.

View Full Paper

Ask AI

Bookmark

This study evaluated the prevalence of claudin 18.2 expression and its prognostic value in pancreatic ductal adenocarcinoma.
Assessed claudin 18.2 expression by immunohistochemistry on tumor samples from 201 patients enrolled in the BIOPAC study (NCT03311776).
Positive expression was defined as moderate or strong staining in ≥75% of tumor cells.
Survival analyses were performed using Kaplan-Meier estimates and multivariable Cox models.
Positive claudin 18.2 expression was found in 27% of the tumors assessed.
In metastatic cases, median overall survival was 9.9 months for CLDN18.2 positive versus 6.3 months for negative (p=0.009).
Median progression-free survival was 6.0 months in the positive group compared to 4.1 months in the negative group (p=0.036).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows the prognostic significance of claudin 18.2 expression in pancreatic adenocarcinoma, indicating potential therapeutic relevance.

Cite This Study

Lim et al. (2026) studied this question.

synapsesocial.com/papers/6a192f2dfab5b468c4418912 https://doi.org/10.1200/jco.2026.44.16_suppl.4188

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows the prognostic significance of claudin 18.2 expression in pancreatic adenocarcinoma, indicating potential therapeutic relevance.

Prevalence and prognostic value of Claudin 18.2 expression in pancreatic ductal adenocarcinoma.

Key Points

Discussion

Implication

Cite This Study

Prevalence and prognostic value of Claudin 18.2 expression in pancreatic ductal adenocarcinoma.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider